AdvisorNet Financial Inc Decreases Position in Johnson & Johnson (NYSE:JNJ)

AdvisorNet Financial Inc reduced its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 16.2% during the 1st quarter, reports. The institutional investor owned 12,168 shares of the company’s stock after selling 2,355 shares during the period. AdvisorNet Financial Inc’s holdings in Johnson & Johnson were worth $1,925,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Keener Financial Planning LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $40,000. WFA Asset Management Corp increased its position in shares of Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new position in Johnson & Johnson during the 4th quarter worth $44,000. Disciplined Equity Management Inc. purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $45,000. Finally, Grayhawk Investment Strategies Inc. raised its holdings in Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after acquiring an additional 259 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Thursday. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Finally, The Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price objective on the stock. Eight analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $174.07.

Get Our Latest Analysis on Johnson & Johnson

Johnson & Johnson Price Performance

NYSE:JNJ traded up $0.42 during trading hours on Monday, hitting $149.17. The company’s stock had a trading volume of 3,019,863 shares, compared to its average volume of 7,400,376. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The company has a market capitalization of $359.00 billion, a PE ratio of 9.27, a PEG ratio of 2.46 and a beta of 0.53. The business’s 50-day moving average is $148.05 and its two-hundred day moving average is $154.33.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.68 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 10.63 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.33%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Read More

Want to see what other hedge funds are holding JNJ? Visit to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.